Weather impacts outcomes in RA: myth or reality? ⛈🌦 Larger study to date 14200 weather-matched PROs Mean PtP PtF PtGA scores higher in winter Few meteorological measures significantly correlated w/ PROs, but correlations are weak @RheumNow #EULAR23 POS0325 https://t.co/7AJmbLQrPW

REMOTRA; REMote moniToring in pReclinical Arthritis 43pts CSA 6 Mo follow up Pts acceptance and usage decrease during time (like many other studies using apps) Composite score of PROs asso w/ risk of RA (...but VPP 12%) Digital follow up of Pre-RA is not ready for clinic yet. https://t.co/o31dVEa5xt

Amazing the chatter in the room for this one. The idea that a new JAKi might genuinely outperform existing JAKi in hard-to-treat RA, without safety cost, is particularly enticing. We all want to see the paper & healthy skepticism of ph2, but watch this space #EULAR2023 @RheumNow https://t.co/jEyk8zqZN8

• https://twitter.com/yuz6yusof/status/1664895728320217088

A mono therapy study RCT of TLL-018 vs #Tofa in RA subanalyses of previous JAKi exposure have not been done. Pts could have failed #Tofacitinib & enrolled so data could be divided to determine how this group responded. Safety looked good in both Rx LB0001 @RheumNow #EULAR2023 https://t.co/4kBHxWmk0q

• https://twitter.com/janetbirdope/status/1664895058120720384

What about a new oral drug in active #rheumatoid #arthritis vs #JAKi #Tofacitinib? TLL-018 a potent JAK1/TYK2 inhibitor was compared with #Tofa and dose ranging of 10, 20, 30 mg of TLL-018 and many Pts w past TNFi and w JAKi. High dose won #EULAR2023 @RheumNow @eular_org LB0001 https://t.co/UXhT7LV1oD